Literature DB >> 35751861

Clinical features associated with thrombotic events in children with myeloproliferative neoplasms.

Kristin A Shimano1, Victoria Vanderpoel1, Hannah Stone1, Linda Resar2, Nicole Kucine3.   

Abstract

In children with MPNs, clots are most common in those with JAK2 mutations and those with polycythemia vera.
© 2022 Wiley Periodicals LLC.

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35751861      PMCID： PMC9378702          DOI： 10.1002/ajh.26646

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   13.265


  10 in total

1.  Age-related differences in disease characteristics and clinical outcomes in polycythemia vera.

Authors:  Brady L Stein; Santosh Saraf; Urszula Sobol; Anna Halpern; Jamile Shammo; Damiano Rondelli; Laura Michaelis; Olatoyosi Odenike; Alfred Rademaker; Anaadriana Zakarija; Brandon McMahon; Jerry L Spivak; Alison R Moliterno
Journal:  Leuk Lymphoma       Date:  2013-01-08

2.  Thrombosis in myeloproliferative neoplasms: update in pathophysiology.

Authors:  Brandi N Reeves; Alison R Moliterno
Journal:  Curr Opin Hematol       Date:  2021-06-28       Impact factor: 3.284

3.  How to manage children and young adults with myeloproliferative neoplasms.

Authors:  T Barbui
Journal:  Leukemia       Date:  2012-01-18       Impact factor: 11.528

Review 4.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

5.  Difficulty distinguishing essential thrombocythaemia from polycythaemia vera in children with JAK2 V617F-positive myeloproliferative neoplasms.

Authors:  Nicole Kucine; Mustafa Al-Kawaaz; Daher Hajje; James Bussel; Attilio Orazi
Journal:  Br J Haematol       Date:  2018-05-16       Impact factor: 6.998

6.  NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.

Authors:  Ruben A Mesa; Catriona Jamieson; Ravi Bhatia; Michael W Deininger; Christopher D Fletcher; Aaron T Gerds; Ivana Gojo; Jason Gotlib; Krishna Gundabolu; Gabriela Hobbs; Brandon McMahon; Sanjay R Mohan; Stephen Oh; Eric Padron; Nikolaos Papadantonakis; Philip Pancari; Nikolai Podoltsev; Raajit Rampal; Erik Ranheim; Vishnu Reddy; Lindsay A M Rein; Bart Scott; David S Snyder; Brady L Stein; Moshe Talpaz; Srdan Verstovsek; Martha Wadleigh; Eunice S Wang; Mary Anne Bergman; Kristina M Gregory; Hema Sundar
Journal:  J Natl Compr Canc Netw       Date:  2017-10       Impact factor: 11.908

7.  Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative Neoplasms.

Authors:  Brady L Stein; Alfred Rademaker; Jerry L Spivak; Alison R Moliterno
Journal:  Thrombosis       Date:  2011-07-24

Review 8.  Novel Pathophysiological Mechanisms of Thrombosis in Myeloproliferative Neoplasms.

Authors:  Brandi N Reeves; Joan D Beckman
Journal:  Curr Hematol Malig Rep       Date:  2021-04-19       Impact factor: 4.213

9.  Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review.

Authors:  Jean-Christophe Ianotto; Natalia Curto-Garcia; Marie Lauermanova; Deepti Radia; Jean-Jacques Kiladjian; Claire N Harrison
Journal:  Haematologica       Date:  2019-01-24       Impact factor: 9.941

Review 10.  Essential Thrombocythemia in Children and Adolescents.

Authors:  Maria Caterina Putti; Irene Bertozzi; Maria Luigia Randi
Journal:  Cancers (Basel)       Date:  2021-12-06       Impact factor: 6.639
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.